Prognosis
Astra Vaccine Shows Less Effect Against South Africa Variant
- Shot doesn’t appear to protect against mild, moderate cases
- Early data of the study is due to be published Monday, FT says
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
AstraZeneca Plc’s Covid-19 vaccine has shown limited efficacy against mild disease caused by the variant first identified in South Africa, according to early data in a small phase trial.